

REMARKS/ARGUMENTS**1. Request for Continued Examination:**

The applicant respectfully requests continued examination of the above-indicated application as per 37 CFR 1.114.

5

2. Rejection of claims 1-3 and 6 under 35 U.S.C. 102(b):

Claims 1-3 and 6 are rejected under 35 U.S.C. 102(b) as being anticipated by Paltieli (US 5,647,373).

10 Response:

Claim 1 has been amended to distinguish from Paltieli. Claim 1 now recites that the intravenous injection device comprises a pedestal and a propeller. The pedestal comprises a housing and a pulse ultrasound probe, whereas the propeller comprises a clipper for clipping a syringe coupled to the propeller, and a motor fixed to the housing of the pedestal and immovable with respect to the pulse ultrasound probe, where the motor contacts with the clipper for conveying the clipper with respect to the housing along the direction of the pulse ultrasonic signals.

15

20

The amended claim 1 emphasizes that the pedestal and the propeller of the claimed invention function as one unit, and are not separable from one another. This amendment is fully supported in Figure 6, claim 3, as well as in paragraph [0026] of the specification.

25

In contrast, Paltieli teaches that an ultrasound transducer 4 and a needle guide 5 move independently of one another, and are not fixed to each other. Therefore, Paltieli does not have a way to prevent the needle from entering into a patient at the wrong angle since the angle of the needle's insertion is independent of the angle of the ultrasound transducer. However, the present invention avoids this problem by making the propeller and the pedestal fixed to each other for ensuring that they move at the same angle.

30

For these reasons, the currently amended claim 1 is patentable over Paltieli. Furthermore, claims 2 and 6 are dependent on claim 1, and should be allowed if claim 1 is allowed. Reconsideration of claims 1, 2, and 6 is respectfully requested.

3. Rejection of claims 4 and 5 under 35 U.S.C. 103(a):


Claims 4 and 5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Paltieli in view of Akhavi (US 4,317,455).

Response:

Claims 4 and 5 are dependent on claim 1, and should be allowed if claim 1 is allowed. Reconsideration of claims 4 and 5 is respectfully requested.

In view of the claim amendments and the above arguments in favor of patentability, the applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Sincerely yours,



Date: 07.05.2007

Winston Hsu, Patent Agent No. 41,526
P.O. BOX 506, Merrifield, VA 22116, U.S.A.
Voice Mail: 302-729-1562
Facsimile: 806-498-6673
e-mail : winstonhsu@naipo.com

Note: Please leave a message in my voice mail if you need to talk to me. (The time in D.C. is 12 hours behind the Taiwan time, i.e. 9 AM in D.C. = 9 PM in Taiwan.)